Loading cancer entity…
Loading cancer entity…
Clinical trials
3,384 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (536)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01745588 | Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma | completed | Phase 2 | 23 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT02619682 | Alternating Ixazomib Citrate and Lenalidomide as Maintenance Therapy After Stem Cell Transplant in Treating Patients With Multiple Myeloma | completed | Phase 2 | 30 | Fred Hutchinson Cancer CenterOTHER | 1 |
| Sep 25, 2026 |
| clinicaltrials |
| NCT01279694 | Trial of Carfilzomib Plus Melphalan and Prednisone in Elderly Untreated Patients With Multiple Myeloma (CARMYSAP)(CARMYSAP) | completed | Phase 1 / Phase 2 | 72 | Nantes University HospitalOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT01936532 | Safety and Efficacy Study of a Triplet Combination of MLN9708, Lenalidomide and Dexamethasone in the Initial Management of Multiple Myeloma (IFM2013-06)(IFM2013-06) | completed | Phase 2 | 42 | Nantes University HospitalOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT05900882 | SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary Disease | completed | Phase 2 | 29 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT04151667 | Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma | completed | Phase 2 | 33 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT01559935 | Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma(CarBiRD) | completed | Phase 2 | 74 | Weill Medical College of Cornell UniversityOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT00461955 | Injection of ex Vivo Amplified G-CSF Mobilised Autologous Peripheral Blood Stem Cell Transplantation(Expansion) | completed | Phase 2 | 13 | University Hospital, BordeauxOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT04975555 | Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy | completed | Phase 2 | 20 | University of Alabama at BirminghamOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT04205409 | Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies | completed | Phase 2 | 20 | University of WashingtonOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT01415882 | Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib | completed | Phase 2 | 165 | Mayo ClinicOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT01242930 | Open Label Study With Imetelstat to Determine Effect of Imetelstat in Patients w/ Previously Treated Multiple Myeloma | completed | Phase 2 | 13 | Geron CorporationINDUSTRY | 1 | Jun 17, 2026 | clinicaltrials |
| NCT03839459 | Denosumab for Smoldering Multiple Myeloma | completed | Phase 2 | 20 | University of RochesterOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT01702831 | Busulfan & Melphalan Conditioning for Autologous Stem Cell Transplant (ASCT) and Lenalidomide Maintenance(BuMelMCRN001) | completed | Phase 2 | 78 | University Health Network, TorontoOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT05032820 | Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma | completed | Phase 2 | 40 | Medical College of WisconsinOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT01053949 | IFM2009-02-Pomalidomide and Dexamethasone Phase 2 Myeloma(IFM2009-02) | completed | Phase 2 | 84 | University Hospital, LilleOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT01222286 | Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple Myeloma(KIRMONO) | completed | Phase 2 | 30 | Innate PharmaINDUSTRY | 1 | May 14, 2026 | clinicaltrials |
| NCT01009840 | IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients | completed | Phase 2 | 30 | Otsuka Pharmaceutical Development & Commercialization, Inc.INDUSTRY | 2 | May 13, 2026 | clinicaltrials |
| NCT02362035 | ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies(KEYNOTE145) | completed | Phase 1 / Phase 2 | 161 | Acerta Pharma BVINDUSTRY | 1 | May 13, 2026 | clinicaltrials |
| NCT04731844 | Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer | completed | Phase 2 | 30 | University of RochesterOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT03413800 | Len/Dex/DLI in Relapsed Multiple Myeloma After Allogeneic Stem Cell Transplant | completed | Phase 2 | 10 | Ciusss de L'Est de l'Île de MontréalOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT03477539 | Daratumumab in Treating Transplant-Eligible Patients With Multiple Myeloma | completed | Phase 2 | 49 | Mayo ClinicOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT05064358 | Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma(DREAMM 14) | completed | Phase 2 | 177 | GlaxoSmithKlineINDUSTRY | 18 | May 5, 2026 | clinicaltrials |
| NCT04083534 | First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM) | completed | Phase 1 / Phase 2 | 43 | Regeneron PharmaceuticalsINDUSTRY | 1 | May 4, 2026 | clinicaltrials |
| NCT02316106 | A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma | completed | Phase 2 | 123 | Janssen Research & Development, LLCINDUSTRY | 11 | Apr 23, 2026 | clinicaltrials |
| NCT01816971 | Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma | completed | Phase 2 | 76 | University of ChicagoOTHER | 2 | Apr 21, 2026 | clinicaltrials |
| NCT01384513 | A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies | completed | Phase 2 | 40 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT02719613 | Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab | completed | Phase 2 | 67 | Bristol-Myers SquibbINDUSTRY | 13 | Apr 15, 2026 | clinicaltrials |
| NCT01453101 | Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma(Flu-Mel-Vel) | completed | Phase 2 | 54 | Hackensack Meridian HealthOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT02405364 | Front-line Therapy With Carfilzomib, Lenalidomide, and Dexamethasone Induction(IFM-CRd) | completed | Phase 2 | 46 | University Hospital, ToulouseOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT02302495 | Study of Carfilzomib Weekly Plus Melphalan and Prednisone in Untreated Symptomatic Elderly Multiple Myeloma(IFM2012-03) | completed | Phase 2 | 32 | University Hospital, LilleOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT02626481 | Study of Daratumumab in Combination With Dexamethasone in Resistant or Refractory Multiple Myeloma(IFM2014-04) | completed | Phase 2 | 64 | University Hospital, LilleOTHER | 2 | Apr 7, 2026 | clinicaltrials |
| NCT01067287 | Blockade of PD-1 in Conjunction With the Dendritic Cell/Myeloma Vaccines Following Stem Cell Transplantation | completed | Phase 2 | 35 | Beth Israel Deaconess Medical CenterOTHER | 2 | Apr 6, 2026 | clinicaltrials |
| NCT01502085 | Vorinostat,Lenalinomide and Dexamethasone in Multiple Myeloma Refractory to Previous Lenalinomide Containing Regimens(RZD) | completed | Phase 1 / Phase 2 | 25 | Hackensack Meridian HealthOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT01242267 | Escalating Doses of Thalidomide in Conjunction With Bortezomib and HIgh Dose Melphalan for BSCT(Thal/Mel/Vel) | completed | Phase 1 / Phase 2 | 29 | Hackensack Meridian HealthOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT01315132 | A Study of Bone Marrow Transplantation Using Fully-Matched Relatives as Donors for Patients With Hematological Malignancies | completed | Phase 2 | 47 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT03441958 | ECT-001 (UM171) Expanded Cord Blood Transplant to Treat High-risk Multiple Myeloma | completed | Phase 1 / Phase 2 | 19 | Ciusss de L'Est de l'Île de MontréalOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT01615029 | Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 45 | Janssen Research & Development, LLCINDUSTRY | 5 | Mar 16, 2026 | clinicaltrials |
| NCT01572480 | Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma | completed | Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Mar 10, 2026 | clinicaltrials |
| NCT03361306 | LCI-HEM-MYE-CRD-002: Carfilzomib-Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple Myeloma | completed | Phase 2 | 15 | Wake Forest University Health SciencesOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT03601078 | An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma(KarMMa-2) | completed | Phase 2 | 312 | CelgeneINDUSTRY | 6 | Mar 4, 2026 | clinicaltrials |
| NCT01919086 | Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma | completed | Phase 2 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT02833610 | A Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency | completed | Phase 2 | 55 | Massachusetts General HospitalOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT05561751 | Ph2, Study to Assess the Safety and Efficacy of GPC 100 and Propranolol With and Without G-CSF for the Mobilization of Stem Cells in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant | completed | Phase 2 | 30 | GPCR Therapeutics, Inc.INDUSTRY | 1 | Feb 12, 2026 | clinicaltrials |
| NCT05014412 | A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to Treatment(MagnetisMM-9) | completed | Phase 2 | 86 | PfizerINDUSTRY | 4 | Feb 10, 2026 | clinicaltrials |
| NCT01237054 | Imaging in MGUS, SMM and MM | completed | Phase 2 | 31 | National Cancer Institute (NCI)NIH | 1 | Feb 6, 2026 | clinicaltrials |
| NCT01745640 | Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14)(IFM2010-02) | completed | Phase 2 | 63 | University Hospital, LilleOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT03159702 | Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation | completed | Phase 2 | 43 | Medical College of WisconsinOTHER | 1 | Jan 27, 2026 | clinicaltrials |
Data updated 4 days agoSource updated Sep 25, 2026source: clinicaltrials